Replies to post #76497 on Biotech Values

[DewDiligence]

if PPHM's pr is not a good enough reason for you to buy, it is also not a bad enough reason for me to sell...

You asked a straight question and the company did not give you a straight answer. That by itself is sufficient reason to sell, IMO. If management can’t give you a straight answer to something as simple as this, why would you have confidence in what they say about anything?

Moreover, the data in this trial are nothing to get excited about. There were 8 confirmed partial responses among the 21 enrolled patients (of whom 17 were deemed to be evaluable), for an intent-to-treat response rate of 38%. Inasmuch as this was an open-label trial and the scans were not read by independent radiologists, it’s reasonable to assume that the scan readers had a vested interest in seeing a high response rate and judged borderline cases to be responses. Thus, the true response rate is this population is likely to be less than the observed 38%.

PPHM has been issuing these kinds of nearly meaningless press releases for as long as I can remember. Some things never change, evidently. Good luck.